Statement by 340B Health President and CEO Ted Slafsky Regarding House E&C Committee 340B Report
Washington, D.C.—340B Health appreciates the work of the House Committee on Energy & Commerce regarding its review of the 340B drug pricing program. We also appreciate the committee’s finding that the 340B program “is an important program that enjoys strong bipartisan support in Congress.” By reducing the prices safety-net hospitals pay for outpatient prescription drugs, the 340B program supports care for millions of low-income and rural Americans. We also thank the committee for its recommendations regarding greater oversight of pharmaceutical manufacturers. We support having a thoughtful conversation about the transparency of the 340B program. We are concerned, however, by recommendations that could limit the scope of the program, cause unnecessary burdens, and hinder the ability of hospitals to provide care to low-income and rural Americans. We look forward to reviewing the report in detail and discussing its findings and recommendations with policymakers from both parties.
Contact: Richard Sorian at firstname.lastname@example.org or (202) 536-2285.